Veklury

Gilead Sciences, Inc. (NASDAQ: GILD) is the first company to receive full FDA approval for a COVID-19 treatment. The Gilead Analyst: Raymond James analyst Steven Seedhouse has a Market Perform rating on Gilead shares.  The Gilead Thesis: Veklury, generic name remdesivir, was ...

The U.S. Food and Drug Administration has approved the antiviral Veklury, commonly known as remdesivir, for the treatment of hospitalized patients with COVID-19. What Happened: Gilead Sciences' (NASDAQ: GILD) remdesivir is approved for patients that are at least 12 years of age. The...

Gilead Sciences, Inc. (NASDAQ: GILD) shares were trading higher Friday after the company announced the publication of final results from the Phase 3, NIAID-sponsored trial of Veklury in adults hospitalized with mild-to-moderate COVID-19. What Happened: The final results of the ACTT-1 study...